CVS Health Plans to Split Into Two Public Companies, Separating Insurance From Retail Pharmacies

CVS Health announced on November 4 that it plans to separate its businesses into two independent, publicly traded companies. One would focus on health insurance, pharmacy-benefit management and healthcare services. The other would operate the company's retail pharmacies and community healthcare services. CVS expects the separation to be completed in the first half of 2028. The transaction is intended to be tax-free for CVS Health and its shareholders under US federal income-tax rules, but it remains subject to customary conditions, including final board approval, an effective registration statement with the Securities and Exchange Commission and confirmation of the expected tax treatment. The plan would reshape one of the largest integrated companies in the US healthcare industry. CVS spent years bringing insurance, prescription-benefit management, retail pharmacies and care delivery under one corporate structure through acquisitions. It now intends to separate the retail pharmacy business from the insurance and healthcare-services operations. CVS says the move will give each company a more focused strategy and greater flexibility. Analysts also point to regulatory scrutiny of vertically integrated healthcare businesses as an important part of the backdrop.

The two businesses have defined boundaries

Under the company's plan, the healthcare-solutions business will retain the CVS Health name. It will include Aetna, CVS Caremark, CVS Specialty, Oak Street Health and Signify Health, along with related value-based care and in-home health operations. The second company will be called CVS Pharmacy. It will include approximately 9,000 retail pharmacies, mail-order pharmacy operations, MinuteClinic locations and the Health100 technology-services business. When the separation is completed, existing CVS Health shareholders are expected to own shares in both companies. Current Chairman and Chief Executive David Joyner will lead the healthcare-solutions company, while Group President Prem Shah will become chief executive of CVS Pharmacy. CVS said both businesses are expected to have investment-grade credit ratings, strong free cash flow and independent capital structures. That would allow each company to make capital-allocation and dividend decisions based on its own priorities. The separation is intended to create two businesses with different operating models. The healthcare-solutions company will combine insurance coverage, prescription-benefit management and care delivery. CVS Pharmacy will focus on the retail pharmacy network and community healthcare services. The company says customers, patients and clients will continue to receive medicines, care, benefits and services without interruption while the separation is being prepared.

Regulatory scrutiny puts vertical integration under pressure

CVS has long argued that combining insurance, pharmacy-benefit management, pharmacies and healthcare services can create efficiencies. A company that operates across several parts of the healthcare system may be able to coordinate prescription coverage, pharmacy services and patient care. But the same structure can raise concerns about conflicts of interest, competition and transparency in prescription-drug pricing. Reuters reported that lawmakers and regulators have increased their scrutiny of vertically integrated healthcare companies. The broader debate concerns whether companies that control multiple parts of the healthcare supply chain can limit competition or contribute to higher costs. MarketWatch and Healthcare Dive also described regulatory scrutiny and the complexity of the integrated business as factors relevant to CVS's decision. CVS management has framed the separation as a strategic choice rather than a forced asset sale or a response to financial distress. The company says the two businesses face different customers, competitive conditions and investment requirements, and that each could operate more effectively with a dedicated leadership team. Regulatory pressure is part of the context, but it would be inaccurate to say that regulators ordered the split or that one factor alone explains the board's decision. The move also reverses part of the consolidation strategy that made CVS a healthcare conglomerate. The company acquired Aetna in 2018 and expanded into primary and value-based care through later acquisitions. The planned separation reflects a reassessment of whether the benefits of owning insurance, pharmacy-benefit management and retail pharmacy operations together still outweigh the complexity of managing them under one public company.

Scale and recent results provide the starting point

CVS said that as of September 30, 2026, it operated approximately 9,000 retail pharmacy locations and more than 1,000 walk-in and primary-care clinics. Its pharmacy-benefit management business served approximately 87 million plan members, while its health-insurance products and related services reached an estimated 37 million people. The retail company would retain the physical pharmacy network, while the healthcare-solutions company would combine insurance, pharmacy-benefit management and care-delivery assets. The company also reported third-quarter revenue of $108.4 billion and adjusted earnings of $2.09 per share. It raised its full-year 2026 adjusted earnings-per-share outlook to at least $8.20. Those figures give investors a snapshot of the business ahead of the proposed separation, but they do not establish how profitable each company will be once the assets are divided. Investors initially reacted negatively to the announcement. Reuters reported that CVS shares fell about 12.5% as the market assessed the surprise decision and the limited details available about the future structure. MarketWatch also reported concerns about the split's rationale, regulatory issues and the outlook for the separate businesses. The share-price decline reflects uncertainty about the transaction and future earnings; it does not by itself prove that the separation will destroy value.

The 2028 target remains conditional

CVS expects to complete the separation in the first half of 2028, but the transaction is still a proposal. It requires final approval from the CVS Health board, an effective Form 10 registration statement filed with the SEC and customary confirmation that the transaction will receive the intended tax-free treatment. The company has acknowledged that the process will require substantial organizational, financial and operational work. Regulatory approvals, market conditions or execution problems could delay or prevent completion. Until the separation is finished, CVS says it will continue operating under its current structure. Customers, patients and business clients are expected to continue receiving their medicines, healthcare, insurance benefits and related services without interruption. Consumers should not expect their pharmacy, insurance card or clinic arrangements to change immediately simply because the company announced the plan. The real test will come after the two companies begin operating independently. Investors will need to assess their debt levels, cash generation, costs, contracts, management structures and ability to negotiate with healthcare partners. Customers will want to know whether pharmacy access, insurance coverage and care coordination remain reliable. The proposed breakup may create more focused businesses, but whether it improves efficiency, competition or healthcare affordability will depend on execution and results after the separation.